

Product datasheet for **TL314498V**

BCAT1 Human shRNA Lentiviral Particle (Locus ID 586)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	BCAT1 Human shRNA Lentiviral Particle (Locus ID 586)
Locus ID:	586
Synonyms:	BCATC; BCT1; ECA39; MECA39; PNAS121; PP18
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	BCAT1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	BC033864 , NM_001178091 , NM_001178092 , NM_001178093 , NM_001178094 , NM_005504 , NM_005504.1 , NM_005504.2 , NM_005504.3 , NM_005504.4 , NM_005504.5 , NM_005504.6 , NM_001178092.1 , NM_001178091.1 , NM_001178094.1 , NM_001178093.1 , BC026006 , BM458559 , NM_001178094.2 , NM_001178091.2 , NM_005504.7 , NM_001178092.2 , NM_001178093.2
UniProt ID:	P54687
Summary:	This gene encodes the cytosolic form of the enzyme branched-chain amino acid transaminase. This enzyme catalyzes the reversible transamination of branched-chain alpha-keto acids to branched-chain L-amino acids essential for cell growth. Two different clinical disorders have been attributed to a defect of branched-chain amino acid transamination: hypervalinemia and hyperleucine-isoleucinemia. As there is also a gene encoding a mitochondrial form of this enzyme, mutations in either gene may contribute to these disorders. Alternatively spliced transcript variants have been described. [provided by RefSeq, May 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).